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1.  TERMS OF REFERENCE
1.1  Purpose
The purpose of the meeting reported here was to 
develop a set of national evidence-based standards 
for assessing and managing patients with potentially 
resectable rectal cancer. This report represents the 
consensus of the multidisciplinary group of Canadian 
rectal cancer experts attending that meeting.
1.2  Participants
A representative group of Canadian rectal cancer experts 
from the key disciplines (surgical, medical and radiation 
oncology, pathology, radiology) involved in managing 
resectable rectal cancer were invited (Table i).
1.3  Target Audience
●    Health care professionals involved in the care of 
patients with potentially curable rectal cancer
●    Stakeholders (provincial cancer agencies, hos-
pitals, and so on) responsible for program and 
funding decisions related to the management of 
potentially resectable cancer
●    Patient advocacy and education groups such as 
the Colorectal Cancer Association of Canada
1.4  Basis of Recommendations
All recommendations are based on a structured 
presentation and discussion of the best available 
evidence.
2.  PREAMBLE
2.1  Application of Recommendations
These standards provide the basis for a discussion 
with patients regarding management options. Treat-
ment plans will depend on a more complete discussion 
of the risks and benefits of proposed therapies with 
individual patients.
Significant progress has been made in improv-
ing outcomes for patients with potentially resectable 
rectal cancer; however, further improvement is neces-
sary. Offering patients the option of participating in 
clinical trials should be a priority.
Optimally, the approach for assessing and man-
aging patients with rectal cancer should involve a 
collaborative, multidisciplinary team (including 
all relevant medical specialties and allied health 
professionals). For example, optimal rectal cancer 
management is predicated on open communication 
and quality assurance between the surgeon and the 
pathologist describing the extent of disease of the 
surgical specimen for optimal postsurgical treat-
ment choices.
Radiologic assessment and imaging should be 
completed within 2–3 weeks to ensure that the ap-
propriate information is available to make timely 
management decisions.
3.  QUESTIONS AND CONSENSUS 
STATEMENTS
Question 1
For complete clinical staging of rectal cancer, what 
should the standard diagnostics and reporting be 
(preoperative assessment)?51
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Consensus Statement 1
All diagnostics should be completed within a timely 
period (42 days to treatment, including imaging within 
the first 2–3 weeks), starting from the date of biopsy.
Services should include:
●    Colonoscopy
●    Imaging
  ●    Computed axial tomography of thorax, abdo-
men, and pelvis AND magnetic resonance 
imaging (mri)
  ●    Slices of 3–4 mm should be routine
  ●    Mesorectal margin measurements or circum-
ferential resection margin (crm) with tumour 
distance should be reported
  ●    Measurements for staging criteria should be 
provided (see the radiology protocol in Ap-
pendix a)
●    When available, endorectal ultrasonography may 
be complementary to mri in some T1/2 patients 
to better delineate T-stage
This statement utilizes Beets–Tan et al. 2001 1, 
Brown et al. 2003 2, Filippone et al. 2004 3, Nagtegaal 
et al. 2002 4, Iafrate et al. 2006 5, Kapiteijn et al. 2001 6, 
and Harisinghani et al. 2003 7.
Question 2
For complete clinical staging of rectal cancer, what 
should constitute standard pathology reporting?
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Consensus Statement 2
For complete clinical staging of rectal cancer, 
synoptic reporting in accordance with the Col-
lege of American Pathologists (cap) protocol for 
the examination of specimens from patients with 
primary carcinomas of colon and rectum, based on 
the American Joint Committee on Cancer and In-
ternational Union Against Cancer TNM, to include 
these points:
●  Total mesorectal excision (tme) quality
●  Macroscopic assessment of mesorectum (com-
plete, partially complete, or incomplete)
●  crm status
  ●    Positive if tumour is at 1 mm or less from the 
crm or if a lymph node with metastasis is at 
1 mm or less from the crm
●    If neoadjuvant therapy was received, pathologic 
tumour response grading should be recorded
For the complete protocol, see the cap template 
(Appendix b).
This statement utilizes Nagtegaal and van 
Krieken 2002 8, Quirke 1998 9, Heald and Ryall 
1986 10, Dworak et al. 1997 11, Washington et 
al. 2008 13, Smith et al. 2008 14, Kapiteijn et al. 
2001 15, Nagtegaal and Quirke 2008 16, Rödel et 
al. 2005 17, Glynne–Jones et al. 2006 18,19, Ruo et 
al. 2002 20, Nagtegaal et al. 2002 21, and Parfitt and 
Driman 2007 22.
Question 3
Which neoadjuvant radiation protocol or protocols should 
be standard when combined with chemotherapy?
Consensus Statement 3
Preoperative neoadjuvant radiotherapy is the stan-
dard of care for clinically staged ii and iii patients. 
Long-course radiation (minimum of 45 cGy over 
5 weeks) with fluoropyrimidine chemotherapy or 
short-course radiation without chemotherapy can 
be considered. A multidisciplinary team approach 
(with or without a tumour board) is important to 
review individual cases and reach consensus on the 
appropriate course of treatment (short- vs. long-
course radiation).
This statement utilizes Bujko et al. 2004 23, 
Marijnen et al. 2003 24, Swedish Rectal Cancer Trial 
1997 25, Bosset et al. 2006 26, Gérard et al. 2006 27, 
and Sauer et al. 2004 28.
Question 4
Which neoadjuvant chemotherapy protocol or proto-
cols should be standard when combined with long-
course radiation?
Consensus Statement 4
The optimal fluoropyrimidine-based chemotherapy 
is based on extrapolation of data from randomized 
trials of combined-modality chemoradiation used in 
the postoperative setting. Use fluoropyrimidine-based 
chemotherapy with long-course radiation. Protracted 
fluoropyrimidine is preferable to bolus 5-fluorouracil 
because of improved tolerability and similar efficacy, 
as seen in the largest and most recent randomized 
trial (int 0144) 29.
This statement utilizes Smalley et al. 2006 29, 
Wong et al. 2008 30, and O’Connell 1994 31.
Question 5
What should be the surgical standard of care for 
rectal cancer?
Consensus Statement 5
All stage ii–iii rectal cancers should be considered for 
neoadjuvant treatment. For all rectal cancers undergo-
ing radical surgery, tme principles must be followed. 
Surgeons treating rectal cancer patients should be 
familiar with the tme surgery. Quality should be as-
sured through independent evaluations by the surgeon 
and the pathologist. Synoptic operative reporting is 
encouraged.
Trans-anal excision represents an oncologic com-
promise for most rectal cancer patients. Consider it 
only in patients with comorbidities, realizing that it 
requires excellent preoperative assessment and high 
intraoperative expertise.
Because trans-anal endoscopic microsurgery is a 
new approach for local excision, patients being treated 
using this approach should preferably be enrolled in 
trials or prospective follow-up studies.
This statement utilizes MacFarlane et al. 1993 32, 
Cecil et al. 2004 33, Dahlberg et al. 1998 34, Martling 
et al. 2000 35, Brown and Daniels 2005 36, Dubé et 
al. 1997 37, Karanjia et al. 1992 38, Ricciardi 2007 39, 
Murphy 2008 40, Ptok 2007 41, van den Brink 2004 42, 
Wibe 2002 43, Okabe 2004 44, and Nash 2009 45.
Question 6
What criteria should be standard for handling, evalu-
ating, and reporting on the surgical specimen?
Consensus Statement 6
The surgeon should be aware of the standard mac-
roscopic evaluation (grades 1, 2, 3) of the surgical 
specimen immediately after removal of the rectum. 
The pathologist receiving the specimen should 
also grade the macroscopic quality of the excision, 
independently of grading by the surgeon. Optimal 
management is predicated on productive, open 
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communication between the surgeon and the pa-
thologist so that quality assurance and appropriate 
mechanisms for evaluation and improvement can 
be achieved (see also consensus statement 5). Col-
laboration is mandatory for optimal evaluation; that 
is, margin assessment, surgical difficulty encoun-
tered, neoadjuvant treatment given to the patient 
must be communicated. (For optimal assessment of 
the specimen, the pathologist has to be informed if 
neoadjuvant therapy was administered.)
This statement takes account of Nagtegaal and 
van Krieken 2002 8, Quirke 1998 9, Dworak 1997 11, 
Washington et al. 2008 13, Smith 2008 14, Kapiteijn 
2001 15, Nagtegaal and Quirke 2008 16, Nagtegaal 
2002 21, and Parfitt and Driman 2007 22.
Question 7
What is the standard adjuvant chemotherapy post 
neoadjuvant treatment and surgery?
Consensus Statement 7
All patients should be considered for 4–6 months of 
fluoropyrimidine-based therapy. Based on extrapola-
tion of phase III trials for adjuvant treatment of colon 
cancer, adjuvant oxaliplatin-based therapy should be 
considered for patients at high risk for recurrence, 
including, but not limited to those who are
●  ypN-positive.
●  crm-positive.
This statement utilizes Sauer et al. 2004 28, Wong 
et al. 2008 29, André et al. 2009 46, and Kuebler et 
al. 2007 47.
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appendix a  RADIOLOGY REPORTING TEMPLATE
MAGNETIC RESONANCE IMAGING PROTOCOL
●    Phased-array coil
●    Field strength: 1.5 T or more
●    High-resolution matrix T2 images
●    Small field of view (<25 cm)
●    Thin section (3–4 mm)
●    Axial, coronal, and sagittal planes
●    Oblique planes perpendicular to the tumour
●    Gadolinium-enhanced imaging
STANDARDIZED IMAGING REPORT
All Tumours
●    Craniocaudal tumour extent
●    Distance from anal verge
●    T stage
●    Circumferential (radial) margin–tumour distance
●    Pelvic viscera and bones
Additions for Low-Rectal and Anorectal Tumours
●    Distance from levator ani
●    Distance from anorectal junction
●    Involvement of sphincter complex
●    Internal sphincter (partial or full)
●    External sphincter and beyond
appendix b  COLLEGE OF AMERICAN 
PATHOLOGISTS PATHOLOGY  
REPORTING TEMPLATE
Note: This consensus guideline is based on College 
of American Pathologists (cap) guideline version 6 
from early 2009. An updated cap guideline (version 7) 
is expected to be available at the end of 2009 and 
should be consulted for additional pathology report-
ing recommendations.
●    Procedure type
  ●    Rectal/rectosigmoid colon (low anterior 
resection)
  ●    Abdominoperineal resection
  ●    Trans-anal disk excision (local excision)
  ●    Other
●    Tumour size
●    Macroscopic tumour perforation
●    Macroscopic assessment of mesorectum (Note 1)
  ●    Complete
  ●    Partially complete
  ●    Incomplete
  ●    Cannot be assessed
●    Histologic type
  ●    Adenocarcinoma
  ●    Mucinous adenocarcinoma
  ●    Signet-ring cell carcinoma
  ●    Small cell carcinoma
  ●    Squamous cell carcinoma
  ●    Adenosquamous carcinoma
  ●    Medullary carcinoma
  ●    Undifferentiated carcinoma
  ●    Other (specify)
●    Histologic grade
  ●    Cannot be assessed
  ●    Low grade (well differentiated to moderately 
differentiated)
  ●    High grade (poorly differentiated to undif-
ferentiated)
●    Tumour depth of invasion (pT)
  ●    pTX: Cannot be assessed
  ●    pT0: No evidence of primary tumour
  ●    pTis: Carcinoma in situ, intraepithelial (no 
invasion)
  ●    pTis: Carcinoma in situ, invasion of lamina propria
  ●    pT1: Tumour invades submucosa
  ●    pT2: Tumour invades muscularis propria
  ●    pT3: Tumour invades through the muscularis 
propria into the subserosa or the nonperito-
nealized perirectal soft tissues
  ●    pT4a: Tumor penetrates the visceral peritoneum
  ●    pT4b: Tumor directly invades adjacent structures
●    Lymph node status (pN)
  ●    pN0: No metastases in ____ lymph nodes
  ●    pN1: ____ (1–3) nodes involved of ____ (total 
number)
  ●    pN2: ____ (≥4) nodes involved of ____ (total 
number)
●    Proximal margin
  ●    Cannot be assessed
  ●    Uninvolved by invasive carcinoma
  ●    Involved by invasive carcinoma
●    Distal margin
  ●    Cannot be assessed
adjuvant chemotherapy for stage II and III colon cancer: results 
from NSABP C-07. J Clin Oncol 2007;25:2198–204.
Correspondence to: Barry Stein, c/o Toula Chondrozou-
makis, 1230–5 Place Ville Marie, Montreal, Quebec   
H3B 2G2.
E-mail: toulac@colorectal-cancer.ca, 
bstein@ccac-accc.ca
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  ●    Uninvolved by invasive carcinoma
  ●    Involved by invasive carcinoma
●    Circumferential (radial) margin (Note 2)
  ●    Cannot be assessed
  ●    Uninvolved
  ●    Involved by invasive carcinoma or a posi-
tive lymph node [tumour or positive lymph 
node present 0–1 mm from margin (or both); 
specify distance to margin (millimetres or 
centimetres)]
●    Lateral margin (for noncircumferential trans-anal 
disk excision)
  ●    Cannot be assessed
  ●    Uninvolved by invasive carcinoma [specify 
distance of invasive carcinoma from closest 
lateral margin (millimetres or centimetres)]
  ●    Involved by invasive carcinoma
●    Neoadjuvant therapy received
  ●    Yes
  ●    No
  ●    Information not available
●    Tumour response to neoadjuvant treatment 
(Note 3)
  ●    Present (% of fibrosis)
  ●    No response identified
●    Vascular (large vessel) invasion
  ●    Not identified
  ●    Present
  ●    Indeterminate
●    Lymphatic (small vessel) invasion
  ●    Not identified
  ●    Present
  ●    Indeterminate
●    Discontinuous extramural extension (irregular tu-
mour nodules in pericolorectal adipose tissue with-
out histologic evidence of residual lymph node)
  ●    Not identified
  ●    Present
  ●    Cannot be determined
NOTES
1.  Mesorectal Envelope
The nonperitonealized surface of the fresh specimen 
is examined circumferentially, and the completeness 
of the mesorectum is scored as complete, partially 
complete, or incomplete 8–10. The entire specimen is 
scored according to the worst area.
●    Complete:  Intact bulky mesorectum with a 
smooth surface. Only minor irregularities of the 
mesorectal surface. No surface defects greater than 
5 mm in depth. No coning towards the distal mar-
gin of the specimen. After transverse sectioning, 
the circumferential margin appears smooth.
●    Nearly complete:  Moderate bulk to the me-
sorectum. Irregularity of the mesorectal surface 
with defects greater than 5 mm, but none ex-
tending to the muscularis propria. No areas of 
visibility of the muscularis propria except at the 
insertion site of the levator ani muscles.
●    Incomplete:  Little bulk to the mesorectum. 
Defects in the mesorectum down to the mus-
cularis propria. After transverse sectioning, the 
circumferential margin appears very irregular.
2.  Circumferential (Radial) Margin
In addition to addressing the proximal and distal 
margins, the circumferential (radial) margin (crm) 
must be assessed for any segment either unencased 
or incompletely encased by peritoneum. The crm 
represents the adventitial soft tissue margin closest 
to the deepest penetration of tumour and is created 
surgically by blunt or sharp dissection of the retro-
peritoneal or subperitoneal aspect respectively. The 
serosal surface (visceral peritoneum) does not con-
stitute a surgical margin.
The distance between the tumour and the crm 
should be reported. The crm is considered negative 
if the tumour is more than 1 mm from the inked 
nonperitonealized surface, but should be recorded 
as positive if tumour is located 1 mm or less from 
the nonperitonealized surface. This description 
includes both tumour within a lymph node and di-
rect tumour extension; however, if crm positivity is 
based solely on intranodal tumour, this fact should 
be stated (cap protocol).
3.  Pathologic Tumour Response to Neoadjuvant 
Therapy (ypN)
The tumour response to neoadjuvant chemoradiation 
therapy should be recorded at least as present, record-
ing the percentage of fibrosis in respect to residual 
tumour (or no response identified).
The entire scarred area of the rectum has to be 
blocked and scrutinized meticulously for any foci 
of residual tumour cells. Acellular mucin pools post 
neoadjuvant therapy are considered to represent a 
pathologic complete response. Tumour regression 
should be assessed only in the primary tumour; 
lymph node metastases should not be included in 
the assessment.
Several grading systems for tumour response are 
available 11,12. A 3-point system showed good inter-
observer reproducibility 12 and may be clinically im-
portant, but it is not yet validated or regularly used in 
patient management and is not required for accredit-
ation purposes for the Commission on Cancer.
PRACTICE GUIDELINE SERIES